Categories

A sample text widget

Etiam pulvinar consectetur dolor sed malesuada. Ut convallis euismod dolor nec pretium. Nunc ut tristique massa.

Nam sodales mi vitae dolor ullamcorper et vulputate enim accumsan. Morbi orci magna, tincidunt vitae molestie nec, molestie at mi. Nulla nulla lorem, suscipit in posuere in, interdum non magna.

InPlay from Briefing.com

Here’s %category%-related post from
cash loan – Yahoo News Search Results:

7:52 am Quad/Graphics: definitive agreement between Quad/Graphics and Courier Corporation terminated (QUAD) : On January 27, 2015, Courier received an unsolicited offer from RR Donnelley of $23.00 per share in cash or stock, subject to pro ration. Quad/Graphics declined to negotiate further. Accordingly, Courier terminated its agreement with Quad/Graphics on February 5, 2015, and will pay Quad/Graphics a $10 million termination fee.

7:51 am Leidos Awarded Contract by NATO to provide systems engineering and integration support for the Ballistic Missile Defense Programme Office; total contract value of $77 mln if all options are exercised (LDOS) :  

7:49 am First Bancorp beats by $0.01 (FBP) : Reports Q4 (Dec) earnings of $0.12 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.11.

Provision for loan and lease losses for the quarter decreased by $3.1 million to $23.9 million, mainly reflecting a reduction in net charge-offs, reserve releases due to improvements in the risk classification of certain commercial and industrial loans, and a decline in the migration of commercial mortgage loans to a worse loan classification.Non-performing assets decreased by $27.7 million, or 4%, to $716.8 million.Non-performing loans, including non-performing loans held for sale, decreased by $35.6 million to $578.5 millionNew non-performing loan inflows decreased by $16.9 million to $64.2 million, or 21%, compared to inflows of $81.1 million in the third quarter of 2014.Total capital, Tier 1 capital, and leverage ratios of 19.16%, 17.89%, and 12.54%, respectively, as of December 31, 2014. Common equity Tier 1 capital ratio of 14.93% and tangible common equity ratio of 10.35% as of December 31, 2014.

7:45 am PMFG Inc misses by $0.06, beats on revs; raises FY15 revs above consensus (PMFG) : Reports Q2 (Dec) loss of $0.06 per share, $0.06 worse than the Capital IQ Consensus Estimate of ($0.00); revenues rose 38.2% year/year to $40.9 mln vs the $37.4 mln consensus.

The year over year growth in revenue is largely attributed to increased revenue in the United States and EMEA regions. The acquisition of the assets of CCA Combustion Systems (“CCA”) in March 2014 combined with higher demand for environmental solutions resulted in a greater than 150 percent increase in revenue in the Environmental Systems operating segment. Increased demand for steam separators utilized in the nuclear power generation industry and oily water separation solutions for the oil production industry resulted in a nearly nine percent year over year increase in the Process Products operating segment revenue.

Co issues

upside guidance

for FY15, raises FY15 revs to $160-170 mln from $150-160 mln vs. $158.99 mln Capital IQ Consensus, with the increase over prior projections largely attributed to the continued strength of our Environmental Systems segment..

“we remain cautious with regard to the impact of lower relative oil and natural gas prices, timing and trajectory of the natural gas infrastructure build-out in China and the timing of certain nuclear re-licensing and upgrade projects… Gross margins in the back half of the year are anticipated to be in line with those recognized in the first half of the fiscal year. The improvement in margin over the Company’s guidance issued in September 2014 is attributed in part to the operational initiatives that first began in the second half of fiscal 2014. Operating expenses are expected to decline modestly over the back half of the year as we reduce the spending on information technology expansion and operational improvement initiatives. 

7:42 am Suburban Propane misses by $0.28, misses on revs (SPH) : Reports Q1 (Dec) earnings of $0.92 per share, $0.28 worse than the Capital IQ Consensus Estimate of $1.20; revenues fell 19.6% year/year to $422.9 mln vs the $481.11 mln consensus.

Revenue declined primarily due to lower retail propane and fuel oil volumes sold and, to a lesser extent, lower retail selling prices associated with lower wholesale product costs.
The first quarter of fiscal 2015 was characterized by a rapidly declining commodity price environment and unseasonably warm weather throughout much of the quarter. In particular, the month of December 2014 was one of the warmest on record, thus negatively impacting volumes sold in the quarter. The impact of lower volumes was somewhat offset by higher margins resulting from the sharp decline in wholesale product costs and savings in operating expenses.” “With the lower commodity price environment experienced during Q1 of FY15, we funded all working capital needs from cash on hand without the need to borrow under our revolving credit facility, and ended the quarter with $62.0 million of cash. With the heart of the fiscal 2015 heating season still ahead, our personnel are poised to react as the weather pattern returns to more normal temperatures reflective of the season.” 

7:41 am Belden beats by $0.03, reports revs in-line; guides Q1 EPS in-line, revs below consensus; guides FY15 EPS in-line, revs below consensus (BDC) : Reports Q4 (Dec) adjusted earnings of $1.24 per share, $0.03 better than the Capital IQ Consensus Estimate of $1.21; revenues rose 19.4% year/year to $608.9 mln vs the $603.02 mln consensus.

Guidance: Co issues mixed guidance for Q1, sees EPS of $0.94-$1.04 vs. $1.03 Capital IQ Consensus Estimate; sees Q1 revs of $565-$585 vs. $595.62 mln Capital IQ Consensus Estimate.

Co issues mixed guidance for FY15, sees EPS of $5.28-$5.58 vs. $5.51 Capital IQ Consensus Estimate; sees FY15 revs of $2.475-$2.525 bln vs. $2.58 bln Capital IQ Consensus Estimate.

7:40 am Graphic Packaging beats by $0.06, reports revs in-line (GPK) : Reports Q4 (Dec) earnings of $0.21 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus Estimate of $0.15; revenues fell 6.9% year/year to $1 bln vs the $1 bln consensus. 

Q4 Adjusted EBITDA increased to $171.8 million versus $158.3 million in the prior year period. Capital Allocation Plan: The Company’s recently approved capital allocation plan includes the initiation of a $0.05 per share quarterly dividend. The first cash dividend is payable April 5, 2015 to stockholders of record on March 15, 2015. The capital allocation plan also includes a share repurchase program under which management may repurchase up to $250 million of shares.

7:40 am Valero Energy Partners beats by $0.04, beats on revs (VLP) : Reports Q4 (Dec) earnings of $0.32 per share, $0.04 better than the Capital IQ Consensus Estimate of $0.28; revenues rose 3.4% year/year to $34.18 mln vs the $32.98 mln consensus.

Strategic Update

The Partnership expects to increase its growth by completing $1 billion in acquisition transactions from subsidiaries of Valero in 2015. As a result, the Partnership expects to deliver annualized fourth quarter 2015 EBITDA of approximately $200 million, or 111 percent higher than its fourth quarter 2014 annualized EBITDA of $95 million.

7:39 am Perrigo beats by $0.05, misses on revs; guides FY15 EPS in-line (PRGO) : Reports Q2 (Dec) earnings of $1.82 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $1.77; revenues rose 9.5% year/year to $1.07 bln vs the $1.09 bln consensus. Co issues in-line guidance for FY15, sees EPS of $7.25-7.45, excluding non-recurring items, vs. $7.37 Capital IQ Consensus Estimate.

7:38 am Cummins beats by $0.05, beats on revs; guides FY15 revs below consensus; Co Plans to return 50% of operating cash flow to shareholders in 2015 (CMI) : Reports Q4 (Dec) earnings of $2.56 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $2.51; revenues rose 11.2% year/year to $5.1 bln vs the $5.04 bln consensus.

Revenues for the full year were a record $19.2 billion, 11% higher than 2013. Acquisitions contributed 3 percent to revenue growth. Revenues in North America increased 20 percent and international sales grew 2 percent. Within international markets, growth in China more than offset weaker demand in Brazil and India.”We reported record revenues in 2014 despite weak economic conditions in several of our most important international markets,” said Chairman and CEO Tom Linebarger. “Revenues grew 11% as demand in on-highway markets in North America improved, we continued executing our distributor acquisition strategy, and we delivered strong growth in China driven by new products. We continued to invest in future growth, reflecting our commitment to technology and product leadership, while growing EBIT faster than sales.” 
Co issues downside guidance for FY15, sees FY15 revs growth of +2-4%, which equates to ~$19.6-20.0 bln vs. $20.98 bln Capital IQ Consensus Estimate.

7:37 am MSCI beats by $0.01, misses on revs; provides FY15 guidance (MSCI) : Reports Q4 (Dec) earnings of $0.49 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus Estimate of $0.48; revenues rose 6.0% year/year to $251.1 mln vs the $255.93 mln consensus.

Full-year 2015 Adjusted EBITDA Expenses, are expected to be in the range of $620-640 mln.
Full-year 2015 interest expense, including the amortization of financing fees, is expected to be approximately $45 mln
Full-year 2015 cash flow from operations is expected to be in the range of $275-325 mln
Full-year 2015 capital expenditures, including software capitalization, are expected to be in the range of $55-65 mln

7:35 am Nu Skin announces dividend increase to $0.35/share from $0.345/share (NUS) :  

7:35 am Alliance Data beats by $0.13, reports revs in-line; guides Q1 EPS below consensus, revs in-line; guides FY15 EPS below consensus, revs below consensus (ADS) : Reports Q4 (Dec) earnings of $3.45 per share, excluding non-recurring items, $0.13 better than the Capital IQ Consensus Estimate of $3.32; revenues rose 30.2% year/year to $1.49 bln vs the $1.49 bln consensus.

Co issues guidance for Q1, sees EPS of $3.40 vs. $3.48 Capital IQ Consensus Estimate; sees Q1 revs of $1.54 bln vs. $1.55 bln Capital IQ Consensus Estimate. Co issues downside guidance for FY15, sees EPS of $14.80 vs. $14.94 Capital IQ Consensus Estimate; sees FY15 revs of $6.5 bln vs. $6.61 bln Capital IQ Consensus Estimate.

7:35 am Enanta Pharmaceuticals misses by $1.64, misses on revs (ENTA) :

Reports Q4 (Dec) earnings of $2.18 per share, $1.64 worse than the Capital IQ Consensus Estimate of $3.82; revenues rose 8511.1% year/year to $77.5 mln vs the $86.62 mln consensus. Enanta expects that its current cash, cash equivalents and marketable securities will be sufficient to meet its anticipated cash requirements for at least the next 24 months. “With a third potential HCV regimen approval anticipated in Japan later this year, and our next generation protease inhibitor candidate expected to advance into phase 3 studies this year as well, Enanta expects to have a portfolio of revenue-producing assets to support our research and development in new therapeutic areas of growth, beginning with our new NASH program targeting candidate selection for later this year.”

7:33 am Estee Lauder beats by $0.08, beats on revs; guides Q3 EPS below consensus; guides FY15 EPS below consensus (EL) : Reports Q2 (Dec) earnings of $1.13 per share, $0.08 better than the Capital IQ Consensus Estimate of $1.05; revenues rose 0.9% year/year to $3.04 bln vs the $3 bln consensus.

Co issues downside guidance for Q3, sees EPS of 0.45-0.50 vs. $0.67 Capital IQ Consensus Estimate; Net sales are forecasted to increase between 6% and 7% in constant currency.Co issues downside guidance for FY15, sees EPS of $2.72-2.80 vs. $2.86 Capital IQ Consensus Estimate; Net sales are forecasted to grow between 2% and 3% in constant currency. 

7:33 am IntercontinentalExchange reports EPS in-line, beats on revs (ICE) : Reports Q4 (Dec) earnings of $2.54 per share, in-line with the Capital IQ Consensus Estimate of $2.54; revenues rose 49.3% year/year to $800 mln vs the $783.07 mln consensus. Included in this amount are transaction and clearing revenues, less transaction-based expenses, of $479 million. Consolidated data services fee revenues for the fourth quarter of 2014 were $174 million, consolidated listings revenues were $95 million and consolidated other revenues were $52 million.

ICE expects full year 2015 combined Data Services and Listings revenue growth of ~ $100 million, excluding acquisitions. ICE expects fourth quarter 2014 acquisitions to contribute $50 million to $55 million in incremental 2015 revenues and $40 million to $45 million in incremental 2015 expenses.

7:32 am Veracyte announces the publication of data demonstrating the analytical and clinical validity of Afirma BRAF (VCYT) : In the new study, researchers evaluated 535 FNA samples using both the Afirma RNA-based classifier and a sensitive, standard PCR DNA-based test. The Afirma BRAF RNA-based classifier accurately determined the presence or absence of the BRAF V600E DNA mutation with equal performance, but with a lower non-diagnostic rate than the DNA-based test (7.6 percent vs. 24.5 percent). In addition, the Afirma BRAF classifier has broader clinical utility: Because it uses a genomic expression signature associated with altered BRAF signaling, it has the potential to detect BRAF mutations other than V600E.

7:32 am MGP Ingredients articulates five-year strategic plan (MGPI) : “First, we intend to maximize the value of our current production volumes. In particular, we want to take advantage of favorable macro trends, such as the growth of the American whiskey category. This category includes bourbon, rye and Tennessee whiskeys and has been expanding at more than a 4.5 percent compound annual rate over the past five years.”

The co noted that the growth plans are complemented by planned investments in operations and by an emphasis on risk mitigation, “We expect capital expenditures largely to focus on improving operational reliability and reducing risk. In addition, we also plan to build our aged whiskey inventory. As needed to support our plans, we will add staff and capabilities in sales and marketing, as well as research and development.”

7:31 am Ebix announces the expansion of total commitments under its existing credit facility from $150 mln to $190 mln, to fund its growth and share repurchase initiatives (EBIX) : The $40 million increase in total commitments was the result of existing and new lender relationships.

7:31 am TASER announced the purchase of 700 AXON Flex body cameras as well as 700 five-year Unlimited and RMS Integration licenses to EVIDENCE.com by the Maricopa County Sheriff’s Office (TASR) : The order was received in the first quarter of 2015 and is expected to ship in the first quarter of 2015

7:30 am Thermo Fisher has acquired Advanced Scientifics, a global provider of single-use technologies for customized bioprocessing solutions, for $300 mln in cash (TMO) : Advanced Scientifics had ~$80 million in 2014 revenue and will be integrated into Thermo Fisher’s Life Sciences Solutions Segment. The company expects accretion to its adjusted earnings per share from the acquisition to be immaterial.

7:28 am Aer Lingus January 2015 traffic statistics (AIRXY) : Y/Y January changes were reported as follows:

Total Passengers decreased 4.5% from 572K to 546KTotal RPK increased 5% from 807 mln to 847 mln Total ASK increased 1.2% from 1,214 mln to 1,229 mlnTotal Passenger load factor increased 2.4% from 66.5% to 68.9%

7:23 am Broadridge Financial beats by $0.03, beats on revs; reaffirms FY15 guidance (BR) : Reports Q2 (Dec) earnings of $0.32 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus Estimate of $0.29; revenues rose 10.4% year/year to $574.6 mln vs the $551.42 mln consensus.

Broadridge is reaffirming its full year guidance and expects:

Co reaffirms guidance for FY15, sees EPS of $2.42-2.52 vs. $2.49 Capital IQ Consensus Estimate; reaffirms total revenue growth in the range of 4-6% Adjusted Pre-tax margins in the range of 17.3% to 17.7%, and Pre-tax margins in the range of 16.4% to 16.8% Free cash flows in the range of approximately $320 million to $370 million
Recurring revenue closed sales in the range of $110 million to $150 million

7:21 am Sally Beauty announces CEO transition; COO Chris Brickman to succeed Gary Winterhalter (SBH) : Mr. Brickman has been a member of the Sally Beauty Holdings Board of Directors since September 2012 and has served as the Company’s President and COO since June 2, 2014

7:20 am Gartner misses by $0.08, reports revs in-line; guides FY15 below consensus (IT) : Reports Q4 (Dec) earnings of $0.72 per share, excluding non-recurring items, $0.08 worse than the Capital IQ Consensus of $0.80; revenues rose 12.2% year/year to $584 mln vs the $584.04 mln consensus.

Co issues downside guidance for FY15, sees EPS of $2.27-2.46, excluding non-recurring items, vs. $2.79 Capital IQ Consensus; sees FY15 revs of $2.15-2.205 bln vs. $2.23 bln Capital IQ Consensus.

7:19 am Sally Beauty misses by $0.03, misses on revs (SBH) : Reports Q1 (Dec) earnings of $0.35 per share, $0.03 worse than the Capital IQ Consensus Estimate of $0.38; revenues rose 2.6% year/year to $964.5 mln vs the $975.12 mln consensus.

Fiscal 2015 first quarter sales increase is attributed to same store sales growth and the addition of new stores.The unfavorable impact from changes in foreign currency exchange rates in the fiscal 2015 first quarter was $12.0 million, or 1.2% of sales.Consolidated same store sales growth in the fiscal 2015 first quarter was 2.3%.

7:18 am On The Wires (:WIRES) :

Acura Pharmaceuticals (ACUR) announced the launch of their second pseudoephedrine product, NEXAFED Sinus Pressure + Pain. NEXAFED Sinus Pressure + Pain [pseudoephedrine HCI 30mg + acetaminophen 325mg] is a meth-resistant immediate-release tablet that effectively relieves congestion due to colds and allergies, as well as pain and/or fever associated with colds and sinus headaches. The Howard Hughes Corporation (HHC) received approval today for its fifth mixed-use project, the second residential and commercial development in Phase Two of the Ward Village Master Plan. Genomic Health (GHDX) announced that, as of April 1, 2015, the Oncotype DX test will be available to eligible breast cancer patients through the National Health Service in England as the only multi-gene breast cancer test recommended by the National Institute for Health and Care Excellence for use as an option to assist in chemotherapy treatment decision-making.Oxford Immunotec (OXFD) announced the first patients have been enrolled in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec’s T-SPOT.CMV and T-SPOT.PRT products.Yandex (YNDX) has released a new app that helps drivers in Moscow find a parking space and pay for the service without leaving their car.JinkoSolar (JKS) announced that it will provide 2 MW of smart modules to IDEC Corporation, a Japanese designer and manufacturer of control automation products, for a ground mounted solar PV project in Nishinomiya, Hyogo Prefecture, Japan. The project, which will comprise of 7,644 JinkoSolar polycrystalline smart modules equipped with TIGO Optimizer smart component, is currently the largest PV project equipped with all smart modules in Japan.Merge Healthcare (MRGE) announced a partnership with ICT Health. Together, Merge and ICT Health will deliver high quality, affordable imaging solutions to hospitals and clinics in the Middle East, North Africa, and India. 

7:18 am Sirius XM Radio beats by $0.01, reports revs in-line; guides FY15 revs below consensus (SIRI) : Reports Q4 (Dec) earnings of $0.03 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.02; revenues rose 9.1% year/year to $1.09 bln vs the $1.08 bln consensus. Co issues downside guidance for FY15, sees FY15 revs of approximately $4.40 bln vs. $4.48 bln Capital IQ Consensus Estimate.

7:15 am Lazard beats by $0.22, beats on revs (LAZ) : Reports Q4 (Dec) earnings of $1.29 per share, excluding non-recurring items, $0.22 better than the Capital IQ Consensus Estimate of $1.07; revenues rose 4.1% year/year to $645.8 mln vs the $617.43 mln consensus.

Record M&A and Other Advisory 2014 operating revenue of $1,011 mln, up 31% from full-year 2013; fourth-quarter operating revenue of $297 mln, up 17% from prior-year periodRecord Asset Management 2014 operating revenue of $1,120 mln, up 9% from full-year 2013; fourth-quarter operating revenue of $284 mln, down 3% from prior-year period Assets under management of $197 bln as of December 31, 2014, up 5% from December 31, 2013, and flat to September 30, 2014; net inflows of $11.3 bln for full-year 2014 and $3.1 bln for fourth-quarter 2014

7:15 am Apollo Global Management reports Q4 (Dec) results, misses on revs (APO) : Reports Q4 (Dec) earnings of $0.23 per share, may not be comparable to the Capital IQ Consensus Estimate of $0.39; revenues fell 63.0% year/year to $294.1 mln vs the $391.48 mln consensus. 

U.S. GAAP results for the fourth quarter ended December 31, 2014 included net income attributable to Apollo Global Management, LLC of $22.2 million, or $0.04 per Class A share, compared to $159.2 million, or $0.94 per Class A share, for the same period in 2013. Apollo reported ENI after taxes of $93.8 million for the fourth quarter ended December 31, 2014, compared to $444.0 million for the same period in 2013. The $350.2 million decrease in ENI after taxes was driven by lower Incentive Business ENI, partially offset by an increase in Management Business ENI. Total revenue for Apollo’s combined segments was $294.1 million for the fourth quarter ended December 31, 2014, a decrease of $528.4 million, or 64%, compared to the same period in 2013, due to a decrease in Incentive Business revenues of $531.8 million primarily due to a $418.4 million decrease in unrealized carried interest. Total expenses for Apollo’s combined segments were $183.7 million for the fourth quarter ended December 31, 2014, a decrease of $201.2 million, or 52%, compared to the same period in 2013, primarily driven by a decrease in profit sharing expense resulting from the decline in carried interest income.

7:13 am EQT Midstream Partners beats by $0.11, reports revs in-line (EQM) : Reports Q4 (Dec) earnings of $1.12 per share, $0.11 better than the Capital IQ Consensus Estimate of $1.01; revenues rose 38.4% year/year to $112.14 mln vs the $111.69 mln consensus.

7:13 am Malibu Boats beats by $0.01, beats on revs (MBUU) :

Reports Q4 (Dec) earnings of $0.26 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.25; revenues rose 26.3% year/year to $55.5 mln vs the $52.57 mln consensus. Net sales per unit for the second quarter of fiscal 2015 decreased 1.3% to $65,506 compared to the second quarter of fiscal 2014, while net sales per unit in the U.S. increased 1.6% over the same period in fiscal 2014. “Looking ahead, we believe we are well positioned for the peak retail selling season. Early boat shows have gone well and the industry could benefit from lower gas prices and more normalized spring weather in the northern markets. While the strong U.S. currency could have some impact and flatten our international sales, we believe strong domestic demand will offset this.”

7:12 am S&P futures vs fair value: +4.50. Nasdaq futures vs fair value: +3.00. :

7:12 am European Markets : FTSE…6,834.99…-25.30-0.40%.  DAX…10,873.73…-37.10-0.30%.

7:12 am Asian Markets : Nikkei…17,504.62…-174.10-1.00%.  Hang Seng…24,765.49…+85.70+0.40%.

7:11 am Teva Pharma beats by $0.01, reports revs in-line (TEVA) : Reports Q4 (Dec) earnings of $1.31 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus Estimate of $1.30; revenues fell 4.8% year/year to $5.17 bln vs the $5.15 bln consensus.

Q4 non-GAAP operating income margin came in at 28.9%, compared to 25.0% in the year ago period.Global sales of Copaxone, the leading multiple sclerosis therapy in the U.S. and globally, amounted to $1.1 billion, a decrease of 2% YoY, but an increase of 3% in local currency terms. In the US, sales of Copaxone amounted to $835 million, up 4% YoY. 

7:10 am Group 1 Auto beats by $0.33, beats on revs (GPI) : Reports Q4 (Dec) earnings of $1.67 per share, excluding non-recurring items, $0.33 better than the Capital IQ Consensus Estimate of $1.34; revenues rose 11.4% year/year to $2.54 bln vs the $2.47 bln consensus. 

New vehicle revenues increased 9.9 percent on 8.4 percent higher unit sales. New vehicle gross profit increased 13.1 percent to $83.2 million as margins rose 4.4 percent or $83 per unit, to $1,973.

7:09 am Entergy misses by $0.07, beats on revs; guides FY15 EPS in-line (ETR) : Reports Q4 (Dec) operating earnings of $0.75 per share, excluding non-recurring items, $0.07 worse than the Capital IQ Consensus Estimate of $0.82; revenues rose 5.2% year/year to $2.83 bln vs the $2.72 bln consensus.

Co issues in-line guidance for FY15, sees EPS of $5.10-5.90 vs. $5.34 Capital IQ Consensus Estimate.

7:09 am Michael Kors beats by $0.15, misses on revs, comps; guides Q4 EPS below consensus (KORS) : Reports Q3 (Dec) earnings of $1.48 per share, $0.15 better than the Capital IQ Consensus Estimate of $1.33; revenues rose 30.9% year/year to $1.26 bln vs the $1.3 bln consensus.  On a constant currency basis, total revenue increased 32.6%.

Retail net sales increased 37.0% to $689.4 million driven by 114 net new store openings since the end of the third quarter of fiscal 2014, e-commerce sales from the recently launched U.S. e-commerce site and an…8.6% increase in comparable store sales vs. +12.6% consensus.Wholesale net sales increased 24.4% to $573.8 million and on a constant currency basis, wholesale net sales grew 26.4%. Revenue in North America increased 22.6% to $1.1 billion, with a 6.0% increase in comparable store sales. European revenue grew 72.1% to $241.4 million, with comparable store sales increasing 21.2%. Revenue in Japan increased 72.1% to $16.0 million, with comparable store sales growth of 35.4%.

Co issues

downside guidance

for Q4, sees EPS of $0.89-0.92 vs. $0.94 Capital IQ Consensus; sees Q4 revs of $1.05-1.08 bln vs. $1.15 bln Capital IQ Consensus Estimate. This assumes a comparable store sales increase of mid-single digits on a reported basis vs. +12% consensus and an increase of high single digits on a constant currency basis

Company repurchased 5,068,813 shares of the Company’s ordinary shares for ~$399.9 million.

7:08 am Xylem beats by $0.02, beats on revs; guides FY15 EPS below consensus, revs below consensus (XYL) : Reports Q4 (Dec) earnings of $0.62 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus Estimate of $0.60; revenues rose 0.9% year/year to $1.04 bln vs the $1.02 bln consensus.

Co issues downside guidance for FY15, sees EPS of $1.85-1.95 vs. $2.06 Capital IQ Consensus Estimate; sees FY15 revs of $3.7 bln vs. $3.93 bln Capital IQ Consensus Estimate.

7:07 am Dupont Fabros Tech reports FFO in-line, beats on revs; guides Q1 FFO in-line; guides FY15 FFO below consensus (DFT) : Reports Q4 (Dec) funds from operations of $0.62 per share, in-line with the Capital IQ Consensus Estimate of $0.62; revenues rose 8.7% year/year to $108 mln vs the $106.66 mln consensus.

Co issues in-line guidance for Q1, sees FFO of $0.59-0.63 vs. $0.63 Capital IQ Consensus Estimate. Co issues downside guidance for FY15, sees FFO of $2.27-2.47 vs. $2.57 Capital IQ Consensus Estimate. Same store revenue growth of 7.3% when comparing Q4 2014 to Q4 2013, 10.5% year over year. Executed and commenced two leases totaling 2.28 MW and 10,587 CRSF and executed two pre-leases totaling 5.68 MW and 25,916 CRSF. Both leases and one of the pre-leases were disclosed in our Q3 earnings release. Guidance Details: Both the higher and lower end of the range assume no revenue from the customer who has halted base rent payments. Contractual revenue from this customer is $0.16 per share in 2015 and any revenue received from this customer in 2015 will increase our Normalized FFO guidance.

7:07 am Galena Biopharma announces that its partner, Orexo AB, has filed a patent infringement lawsuit in United States District Court against Actavis Laboratories (ACT) and Andrx Corporation (GALE) : The lawsuit was filed in response to the Abbreviated New Drug Application filed by Actavis (ACT). In its application, Actavis seeks to market and sell generic versions of Abstral (fentanyl) sublingual tablets in the U.S. prior to the expiration of Orexo’s U.S. patents for Abstral listed in the FDA’s Orange Book. The listed patents are U.S. patents 6,759,059, 6,761,910 and 7,910,132 with expiration dates in September 2019. Galena currently markets Abstral and is the owner of the New Drug Application in the United States.

Because Orexo initiated a lawsuit against Actavis in a timely manner, the FDA is statutorily precluded from approving Actavis’ ANDA for 30 months, or until a district court decision finding the patents invalid or not infringed, whichever occurs earlier.

7:07 am PPL Corp beats by $0.09, beats on revs; guides FY15 EPS below consensus (PPL) : Reports Q4 (Dec) earnings of $0.58 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus Estimate of $0.49; revenues rose 42.7% year/year to $4.02 bln vs the $2.96 bln consensus. Co issues downside guidance for FY15, sees EPS of $2.05-2.25 vs. $2.27 Capital IQ Consensus Estimate.

7:06 am Chesapeake Granite Wash decreases quarterly distribution to $0.4496 from $0.5079 (CHKR) :  

7:06 am Fidelity Nat’l Info reports EPS in-line, revs in-line; guides FY15 EPS in-line, revs in-line (FIS) : Reports Q4 (Dec) earnings of $0.87 per share, excluding non-recurring items, in-line with the Capital IQ Consensus Estimate of $0.87; non-GAAP revenues rose 7.4% year/year to $1.69 bln vs the $1.70 bln consensus. Co issues in-line guidance for FY15, sees EPS of $3.37-3.49, excluding non-recurring items, vs. $3.47 Capital IQ Consensus Estimate; sees FY15 non-GAAP revs of $6.74-6.87 bln vs. $6.86 bln Capital IQ Consensus Estimate.

7:04 am IAMGOLD provides update from its ongoing exploration program at its optioned Monster Lake project (IAG) : During 2014, the Company conducted a multi-phase diamond drilling program totaling 12,761 metres. This news release reports the assay results of the final 17 of the 26 drill holes in the program. The 2014 drilling program was designed to test the direct down-dip and lateral extensions of the 325-Megane mineralized zone, as well as areas along strike within the interpreted structural corridor referred to as the Monster Lake Shear Zone (“MLSZ”).

In 2015, an initial 5,000 metre, winter diamond drilling program is planned which is designed to test selected target areas along the main MLSZ structure to take advantage of the winter access conditions. Further drilling is also planned on the 325-Megane zone to test the continuation of lateral and down-plunge extensions.  Drilling is expected to commence in the coming weeks. 

7:04 am ISIS Pharm earns $10 million milestone payment from Biogen Idec (ISIS) : As ISIS-BIIB4Rx advances in development, Isis is eligible to receive up to $249 million in additional milestone payments and a license fee, including amounts related to the costs of clinical trials. In addition, Isis is eligible to receive double-digit royalties from sales of ISIS-BIIB4Rx.

7:03 am MWI Veterinary Supply beats by $0.05, beats on revs (MWIV) : Reports Q1 (Dec) earnings of $1.57 per share, $0.05 better than the Capital IQ Consensus Estimate of $1.52; revenues rose 16.2% year/year to $798.5 mln vs the $783.79 mln consensus.

Co increased “new placements” of Abaxis diagnostic instruments by 125% to 456 units during the quarter, compared to 203 units in the same period in the prior fiscal year.

7:03 am Neovasc announces that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of Refractory Angina were published in the New England Journal of Medicine (NVCN) : “The results from this rigorously designed trial speak for themselves. They demonstrate a clear clinical benefit and highly safe procedure,” said Dr. Shmuel Banai, Director of Interventional Cardiology in the Cardiology Department at the Tel Aviv Medical Center, Tel Aviv, Israel. “For RA patients, even a 1-grade improvement in CCS class makes a dramatic impact on their quality of life, let alone a 2-grade improvement, which occurred in 35% of the treated patients.”

“We expect commercial distribution of the Reducer in selected European markets to begin shortly and we are also working to advance the Reducer’s clinical and regulatory program in the US.”

7:03 am Snap-On beats by $0.18, beats on revs (SNA) : Reports Q4 (Dec) earnings of $1.97 per share, excluding non-recurring items, $0.18 better than the Capital IQ Consensus Estimate of $1.79; revenues rose 7.5% year/year to $857.4 mln vs the $829.5 mln consensus.

Outlook
SNA expects that capital expenditures in 2015 will be in a range of $80 million to $90 million. Snap-on also anticipates that its full year 2015 effective income tax rate will be at or below its 2014 full year rate.

7:02 am Old Dominion beats by $0.08, reports revs in-line (ODFL) : Reports Q4 (Dec) earnings of $0.81 per share, $0.08 better than the Capital IQ Consensus Estimate of $0.73; revenues rose 21.7% year/year to $721 mln vs the $714.51 mln consensus.

For 2015, co expects capital expenditures to total $463.3 mln, including planned expenditures of $164.7 mln for real estate and service center expansion projects, $271.8 mlnfor tractors, trailers and other equipment and $26.8 mln for technology and other assets.

7:02 am EQT Corp. reports year-end 2014 total proved reserves of 10.7 Tcfe; represents a 2.4 Tcfe net increase over 2013, with a reserve replacement ratio of 590% (EQT) : The Company’s 2014 Marcellus proved reserves increased by 2.3 Tcfe, primarily from wells drilled in 2014, acreage acquisitions, and higher estimated ultimate recoveries per well. For 2014, the EUR of proved Marcellus wells averaged 7.9 Bcfe, with an average lateral length of 4,435 feet; compared to the 2013 EUR of 7.2 Bcfe, with an average lateral length of 4,335 feet. Additional proved reserves increases include 240 Bcfe for Upper Devonian, and 103 Bcfe for the acquired Permian assets. Proved reserve decreases of 199 Bcfe were realized from the divested Nora assets; and 134 Bcfe of undeveloped reserves were removed due to the suspension of the Huron program in 2014.

EQT estimates year-end 2014 total proved, probable and possible reserves at 42.8 Tcfe, an increase of 6.4 Tcfe, or 18%. This increase is primarily due to the acquisition of additional Marcellus acreage.

7:02 am Exterran increases credit facility to $1.05 Bln (EXLP) : Commitments collectively increase the borrowing capacity under the revolving credit facility by $250 mln to $900 mln, with an additional amended credit facility, that matures in May 2018, including a $150 mln term loan facility.

7:01 am Ignyta receives orphan drug designation from FDA for Entrectinib for the treatment of molecularly defined subsets of non-small cell lung cancer (RXDX) : Entrectinib is currently in two Phase I/II clinical trials, the STARTRK-1 trial and the ALKA-372-001 trial. 

7:01 am Rentrak sells pay per transaction business to Vobile for $7 Mln; $1 mln in cash, a $1 mln six month note and Vobile preferred stock with a $5 mln liquidation preference (RENT) :  

7:01 am Hospira: Pfizer (PFE) to acquire Hospira for $90 a share in cash for a total enterprise value of ~$17 bln; expected to be immediately accretive upon closing by $0.10-0.12 per share for the first full year following closing (HSP) : Pfizer (PFE) notes that this strategically complementary combination will add a growing revenue stream and a platform for growth for Pfizer’s GEP business. The expanded portfolio of sterile injectable pharmaceuticals, composed of Hospira’s broad generic sterile injectables product line, including acute care and oncology injectables, with a number of differentiated presentations, as well as its biosimilars portfolio, combined with GEP’s branded sterile injectables, including anti-infectives, anti-inflammatories and cytotoxics, will create a leading global sterile injectables business.

Both sterile injectables and biosimilars are large and growing categories. The global marketplace value for generic sterile injectables is estimated to be $70 bln in 2020. The global marketplace for biosimilars is estimated to be ~$20 bln in 2020Pfizer expects to finance the transaction through a combination of existing cash and new debt, with approximately two-thirds of the value financed from cash and one-third from debt. In addition, Pfizer anticipates the transaction to deliver $800 mln in annual cost savings by 2018. 
The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive upon closing, accretive by $0.10 – $0.12 per share for the first full year following the close of the transaction with additional accretion anticipated thereafter.

6:58 am Teradata beats by $0.01, misses on revs; guides FY15 EPS below consensus, revs below consensus (TDC) : Reports Q4 (Dec) earnings of $0.91 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus Estimate of $0.90; revenues rose 0.3% year/year to $761 mln vs the $778.2 mln consensus.

Co issues downside guidance for FY15, sees EPS of $2.50-2.70, excluding non-recurring items, vs. $2.99 Capital IQ Consensus Estimate; sees FY15 revenues flat to down 2% which equates to roughly $2.68-$2.73 bln vs. $2.83 bln Capital IQ Consensus Estimate.

6:49 am Southern Copper beats by $0.06, reports revs in-line (SCCO) : Reports Q4 (Dec) earnings of $0.43 per share, $0.06 better than the Capital IQ Consensus Estimate of $0.37; revenues fell 4.2% year/year to $1.47 bln vs the $1.48 bln consensus.

During Q4 higher copper, silver and zinc sales volume offset lower metal prices. Net sales for the 4Q14 were $1,471.3 mln, only 0.2% lower than 3Q14 net sales of $1,474.6 mln despite having a 5.5% lower copper price during this period.Full year 2014 net sales were $5,787.7 mln maintaining the same level as in 2013 because of improved operational performance and capital investments that reduced costs and increased copper and molybdenum production in 2014 despite lower prices of copper (-7%), silver (-20%) and gold (-10%).Copper production for 2014 increased 9.7% to 676,599 metric tons from 617,019 metric tons in 2013. In the 4Q14, copper production increased 9.2% to 183,616 metric tons from 168,210 metric tons in 3Q14.”This increase was the result of higher production at our Mexican operations, mainly at the Buenavista mine, and at our Peruvian operations.”

6:47 am Genetic Technologies announced yesterday that its Nasdaq deficiencies had successfully been remediated (GENE) : To regain compliance, the Company undertook a reverse stock split (consolidation) which, when actioned, has the effect of resetting the existing ratio of 1 ADR representing 30 Ordinary shares to 1 ADR representing 150 Ordinary shares. The target date for the ratio change was Monday 19 January, 2015. From January 20 to February 2, 2015, the closing bid price of the Company’s common stock has been at USD 1.00 per share or greater.

6:45 am Kirklands raises Q4 EPS guidance; sees Q4 sales above estimates; promotes Mike Madden to CEO and Adam Holland to CFO (KIRK) : Q4 net sales +14.5% to $178.7 mln vs. $174.4 mln Consensus.

Comparable store sales for the fourth quarter of fiscal 2014, including e-commerce sales, rose 8.2% compared with a flat performance in the prior-year quarter. 

Kirkland’s increased its guidance for the fourth quarter of fiscal 2014 to earnings of $0.84 to $0.87 per diluted share compared with previous guidance of $0.77 to $0.84 vs. $0.84 Consensus.

Mike Madden, currently President and Chief Operating Officer, will be named President and Chief Executive Officer. Mr. Madden will also join the Company’s board of directors, which will be increased from seven to eight members. Robert Alderson will retire from his role as Chief Executive Officer and will remain on Kirkland’s board. Adam Holland, most recently the Vice President of Finance and Chief Accounting Officer, will be appointed Vice President and Chief Financial Officer.

6:37 am Invacare beats by $0.16, reports revs in-line (IVC) : Reports Q4 (Dec) loss of $0.12 per share, excluding non-recurring items, $0.16 better than the Capital IQ Consensus Estimate of ($0.28); revenues fell 3.8% year/year to $318.2 mln vs the $319.8 mln consensus.

While the Company is not giving guidance, it is important to mention that if the Euro continues to be weak compared to prior year, it may negatively impact our 2015 performance, as the European segment was our main driver of profitability and cash flow in 2014. Accordingly, we will monitor and manage cash flow particularly closely. The Company also will work diligently toward improving the profitability of our North America/HME and Asia/Pacific businesses and continuing our quality systems remediation. Status of the consent decree
Regarding the status of the Company’s consent decree with the FDA, CEO commented, ”With the help of the consulting firm we engaged in 2014, our internal subject matter experts are executing our action plans to improve the functionality and capabilities of certain quality subsystems. We have identified the root causes of the issues that need to be addressed in order to achieve sustainable compliance, and we are working through quality implementation plans that are intended to help us achieve the appropriate solution. I am meeting with the teams weekly to drive progress and accountability. We are making progress, but we still have work to do, including process improvements for addressing complaint data, before we can verify the effectiveness of our solutions and complete the third-party expert certification audit.”

6:37 am MAXIMUS beats by $0.07, reports revs in-line; reaffirms FY15 EPS guidance, revs guidance (MMS) : Reports Q1 (Dec) earnings of $0.63 per share, $0.07 better than the Capital IQ Consensus Estimate of $0.56; revenues rose 14.9% year/year to $467 mln vs the $469.23 mln consensus.

Signed contract awards totaled $1.3 billion and the sales pipeline remained strong at $3.6 billion at December 31, 2014. 
Co reaffirms guidance for FY15, sees EPS of $2.25-2.40 vs. $2.33 Capital IQ Consensus Estimate; sees FY15 revs of $1.9-2.0 bln vs. $1.95 bln Capital IQ Consensus Estimate.

6:34 am Apollo Investment beats by $0.01, beats on revs (AINV) : Reports Q3 (Dec) net investment income of $0.24 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.23; total investment income rose 16.3% year/year to $110 mln vs the $105.98 mln consensus.

“Although the liquid credit markets were challenging during the quarter, the volatile environment enabled us to deploy capital at attractive risk-adjusted returns.” Mr. Zelter continued, “Long-term, we remain optimistic about the outlook for providers of flexible capital solutions amidst the growing impact of regulation on the lending landscape.”

6:33 am Coty beats by $0.14, misses on revs (COTY) : Reports Q2 (Dec) earnings of $0.45 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus Estimate of $0.31; revenues fell 4.8% year/year to $1.26 bln vs the $1.28 bln consensus.

2015 Outlook 
Coty is targeting to gradually return to profitable growth. The Company remains firmly focused on growing its power brands around the world behind innovation, strong support levels and improving “in-market” execution. Coty is also intensely focused on cost optimization opportunities to improve profitability and to provide for investment in its power brands. The $200 million of annual savings expected from the Global Efficiency Plan should help the Company make progress against this target over time.

6:32 am Medidata Solutions beats by $0.03, misses on revs; guides FY15 revs in-line (MDSO) : Reports Q4 (Dec) earnings of $0.25 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus Estimate of $0.22; revenues rose 19.6% year/year to $89.2 mln vs the $91.06 mln consensus.

Co issues in-line guidance for FY15, sees FY15 revs of $392-412 mln vs. $408.96 mln Capital IQ Consensus Estimate.

6:29 am On The Wires (:WIRES) :

Applied DNA Sciences (APDN) has completed a campaign for SigNature T DNA marking of pima cotton fibers destined for one of America’s largest retailers. More than 10,000 bales of extra long staple, pima cotton have been securely marked at the fiber level with APDN’s botanically-derived DNA, and are en route to off-shore locations in Asia for conversion to finished goods, that will ultimately be sold at retail this year.Elsevier NV (ENL) announced its agreement to participate in CLOCKSS (Controlled Lots of Copies Keep Stuff Safe) archiving of ebooks. CLOCKSS is a community-governed archive committed to open access.Net 1 UEPS Technologies (UEPS) announced that it has established a new subsidiary in the United Kingdom called Zazoo Limited to oversee the global expansion of Net1’s mobile payments and value-added services businesses, including the activities currently conducted through its Net1 Mobile Solutions business unit based in Johannesburg, South Africa.Accenture (ACN) has unveiled an innovative Proof of Concept using a wearable device to demonstrate a new way for fans to interact with live sport. Designed by Accenture Mobility to provide an in-stadium, non-intrusive experience, the PoC shares curated content to a wearable headset in order to provide real-time, relevant data about the game as it’s being played.IGT (IGT) announced an agreement to install the Company’s pioneering systems solutions at the prestigious Palazzo Club, which is located within the Sheraton Saigon Hotel & Towers, Vietnam. The groundbreaking agreement includes the first installation of IGT’s Advantage Systems in the Vietnam slot club market, introducing this segment to new slot operations capabilities, including in-depth analyses of individual game performance.DaVita Kidney Care, a division of DaVita HealthCare Partners (DVA), announced that the company is a leader in immunizations for kidney care providers and has exceeded its own previous immunization rates for both dialysis patients and teammates. As of Dec. 31, 2014, DaVita Kidney Care achieved the following: Over 92% of patients immunized for seasonal influenza, Over 93% of patients immunized for pneumococcal pneumonia, Over 92% of teammates immunized for seasonal influenzaMobile TeleSystems (MBT) announces that Standard & Poor’s Ratings Services has downgraded the Company’s long-term foreign and local currency corporate credit rating from ‘BBB-‘ to ‘BB+’ following the downgrade of the Russia’s sovereign rating from ‘BBB-‘ to ‘BB+’. The outlook on the MTS’s foreign currency rating and the local currency rating remains negative. Ratings on the Company’s senior unsecured debt were downgraded from ‘BBB-‘ to ‘BB+’.

6:27 am Becton Dickinson beats by $0.10, beats on revs; guides FY15 just below consensus — raises FY15 guidance ex-FX (BDX) : Reports Q1 (Dec) adj. earnings of $1.53 per share, $0.10 better than the Capital IQ Consensus Estimate of $1.43; revenues rose 1.8% year/year to $2.05 bln vs the $2.01 bln consensus.

Co issues downside guidance for FY15, sees EPS of $6.50-6.57, excluding non-recurring items, vs. $6.71 Capital IQ Consensus; sees FY15 revs of flat to -1% to ~$8.36-8.45 bln vs. $8.45 bln Capital IQ Consensus.

The Company estimates that revenues for the full fiscal year 2015 will increase approximately 5.0 percent on a foreign currency-neutral basis, which is an increase from previously issued guidance of 4.5 to 5 percent. The Company expects adjusted diluted earnings per share from continuing operations to grow 9.0 to 10.0 percent on a foreign currency-neutral basis. This is an increase from previously issued guidance of 8.0 to 9.0%.

6:22 am Spectra Energy and Spectra Energy Partners (SEP) announce 2015 business outlook and financial plan (SE) : Co announced their business outlook and 2015-2017 financial plan 

Spectra Energy 2015 distributable cash flow of more than $1.2 billion Dividend increase of 14 cents per share annually, or 9%, through 2017 at Spectra Energy; dividend coverage of 1.2x in 2015 and 1.0x per year in 2016 and 2017 SEP distributable cash flow in 2015 of $1.1 billion with a compound annual growth rate (CAGR) of 12.7% through 2017 Distribution increases of one and a quarter cents each quarter, or 8% annually, through 2017 at SEP; distribution coverage of 1.1x in 2015 and 1.02x in 2016 and 2017 2015 Spectra Energy enterprise-wide EBITDA of more than $2.8 billion; with a CAGR of 10.5% through 2017 Investment of approximately $8 billion in expansion capital (CapEx) over the plan period with $2.5 billion invested in 2015 and $2.8 billion in both 2016 and 2017SEP’s share of CapEx is about 75% in 2015; approximately 60% in 2016, and nearly 70% in 2017 

6:21 am Conns sees Q4 revs below consensus; Jan same store sales +4.9%; Greater than 60-day delinquency was flat as of January 31, 2015 YoY (CONN) :

Co issues downside guidance for Q4 (Jan), sees Q4 (Jan) revs of $350.5 mln vs. $426.19 mln Capital IQ Consensus Estimate. Co reported $93.6 million in total retail net sales for the month ended January 31, 2015, a 16.8% increase compared to the same prior year period.”Greater than 60-day delinquency was flat as of January 31, 2015 compared to December 31, 2014 without the benefit of meaningful portfolio growth. Less than 60-day delinquency at January 31, 2015 declined compared to last month and continues to be well below the same period a year ago. Collections were strong for the month of January as our payment rate increased above the prior year January, and was flat for the quarter compared to a year ago.” “Same store sales for the month increased 4.9% against an increase of 28.2% in January last year. Same store sales increased 1.3% for the quarter and 8.0% for fiscal 2015. We continue to experience headwinds from tighter underwriting compared to a year ago, with an estimated impact of approximately 5-7% in the quarter. Tighter underwriting, along with additional store openings, mostly impacted our Arizona and New Mexico stores. Excluding Arizona and New Mexico locations, same store sales increased 6.9% for the month.”

6:18 am W.R. Grace beats by $0.12, misses on revs; guides FY15 EPS in-line (GRA) : Reports Q4 (Dec) earnings of $1.37 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus Estimate of $1.25; revenues rose 3.5% year/year to $804.1 mln vs the $839.52 mln consensus.

Co issues in-line guidance for FY15, sees EPS of $5.05-5.45 vs. $5.06 Capital IQ Consensus Estimate.
Expects 2015 Adjusted EBIT to be in the range of $675-705 mln
The company expects 2015 Adjusted Free Cash Flow to be at least $430 mln

6:16 am Dunkin Brands misses by $0.01, reports revs in-line; guides FY15 EPS in-line; announced 15% increase in dividend and $700 mln stock repurchase program (DNKN) : Reports Q4 (Dec) earnings of $0.46 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus Estimate of $0.47; revenues rose 5.5% year/year to $193.2 mln vs the $191.29 mln consensus.

Co issues in-line guidance for FY15, sees EPS of $1.83-1.87 vs. $1.87 Capital IQ Consensus Estimate. Dunkin’ Donuts U.S. comparable store sales growth of 1.4%. BR U.S. comparable store sales growth of 9.3%. DD International comparable store sales growth of 0.3%. Added 260 net new restaurants worldwide including 141 net new Dunkin’ Donuts in the U.S. Dividend and stock repurchase: Board of Directors declares $0.265 first quarter dividend representing a 15% increase over the Company’s fourth quarter 2014 dividend Board of Directors authorized new $700 million share repurchase program. Guidance: The Company expects Dunkin’ Donuts U.S. comparable store sales growth of 1 to 3 percent and Baskin-Robbins U.S. comparable store sales growth of 1 to 3 percent. The Company expects that Dunkin’ Donuts U.S. will add between 410 and 440 net new restaurants, for greater than 5 percent net unit growth, and expects Baskin-Robbins U.S. will add between 5 and 10 net new restaurants.

6:16 am Prestige Brands beats by $0.08, beats on revs; guides FY15 EPS in-line, guides revs to high end of prior range (PBH) : Reports Q3 (Dec) earnings of $0.48 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus Estimate of $0.40; revenues rose 36.4% year/year to $197.6 mln vs the $190.21 mln consensus.

Co issues guidance for FY15, sees EPS of $1.82-1.85 vs. $1.80 Capital IQ Consensus Estimate; sees revenue growth at the high end of prior range of 15-18%.

6:15 am Sequans Communications beats by $0.01, misses on revs; guides Q1 EPS below consensus, revs below consensus (SQNS) :

Reports Q4 (Dec) loss of $0.12 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.13); revenues rose 32.3% year/year to $6.6 mln vs the $7.38 mln consensus. Gross margin was 6.1% (34.7% on a non-IFRS basis) compared to gross margin of 39.4% in the third quarter of 2014, primarily due to the recording of non-cash provisions for slow-moving WiMAX inventory in the amount of $1.9 million, and compared to 43.8% in the fourth quarter of 2013. Co issues downside guidance for Q1, sees EPS of ($0.12) -(0.14) vs. ($0.12) Capital IQ Consensus Estimate; sees Q1 revs of $4-6 mln vs. $7.36 mln Capital IQ Consensus Estimate.  Meaningful sequential revenue growth is expected beginning in the second quarter as new devices are launched in addition to the product already shipping. In addition, discussions with several potential strategic partners are continuing. When finalized, these alliances are expected to contribute financing and incremental revenue.

6:15 am Ball Corp misses by $0.01, beats on revs; unlikely co will attain its long-term 10-15% EPS growth goal in 2015 (BLL) : Reports Q4 (Dec) earnings of $0.84 per share, excluding non-recurring items, $0.01 worse than the Capital IQ Consensus Estimate of $0.85; revenues rose 1.8% year/year to $2.03 bln vs the $1.98 bln consensus. 

“We achieved record free cash flow in excess of $620 million in 2014 and anticipate full-year 2015 free cash flow to be in roughly the same range. Given the strength of our 2014 financial performance, we’ve created a challenging earnings comparison for 2015, especially in the first half when we are ramping up multiple global capital projects and awaiting the award of additional aerospace contracts,” Hayes said. “We expect the second half to be stronger than the first half and it is unlikely we will attain our long-term 10-15 percent earnings per diluted share growth goal in 2015.”

6:11 am Carlisle Cos beats by $0.06, beats on revs; sees FY15 organic sales growth in the mid-to-high single digits with continued EBIT and margin improvement (CSL) : Reports Q4 (Dec) earnings of $0.81 per share, $0.06 better than the Capital IQ Consensus Estimate of $0.75; revenues rose 9.1% year/year to $790 mln vs the $779.89 mln consensus. 

Organic sales growth was 6.0%. The acquisition of LHi Technology reported in the Carlisle Interconnect Technologies (CIT) segment contributed 3.6% to sales in the fourth quarter. The negative impact on net sales from fluctuations in foreign exchange was 0.5%. Higher costs at Carlisle Construction Materials (CCM), lower net sales and EBIT (earnings before interest and income taxes) at Carlisle Brake & Friction (CBF) and a higher effective tax rate in the fourth quarter of 2014 affed earnings. “We look to improve performance in 2015 as we plan for organic sales growth in the mid-to-high single digit percent range with continued EBIT and EBIT margin improvement. We expect the acquisition of Liquid Finishing Brands, as the new Carlisle Fluid Technologies (CFT) segment with annual sales of ~$275 million, to be accretive to our net earnings in 2015. We are planning for capital expenditures of ~$100 million in 2015.

6:10 am ClearSign Combustion disclosed that on February 3, 2015, Stephen E. Pirnat was appointed as President, CEO and Chairman of the Board (CLIR) : Pirnat became a director of the Company in November 2011. Since August 2012, Mr. Pirnat has been Managing Director of Europe, the Middle East and African operations at Quest Integrity Group, a division of Team Industrial Services, a provider of asset integrity management and asset reliability solutions in the refinery, chemical, petrochemical, pipeline and power industries worldwide.

6:08 am Towers Watson beats by $0.24, beats on revs; guides FY15 EPS in-line, reaffirms FY15 revs guidance (TW) : Reports Q2 (Dec) earnings of $1.73 per share, excluding non-recurring items, $0.24 better than the Capital IQ Consensus Estimate of $1.49; revenues rose 7.8% year/year to $957.9 mln vs the $921.16 mln consensus.

Guidance
Co issues raises guidance for FY15, sees EPS of $5.90-6.00 vs. $5.91 Capital IQ Consensus Estimate, up from $5.85-5.97 prior; sees FY15 revs of ~$3.6 bln vs. $3.62 bln Capital IQ Consensus Estimate.

6:08 am CIGNA beats by $0.02, reports revs in-line; guides FY15 EPS in-line, revs in-line (CI) : Reports Q4 (Dec) earnings of $1.69 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus Estimate of $1.67; revenues rose 9.5% year/year to $8.93 bln vs the $8.89 bln consensus.

Co issues in-line guidance for FY15, sees EPS of $8.00-8.40 vs. $8.20 Capital IQ Consensus Estimate; sees FY15 revs of +8-10% to ~$37.7-38.4 bln vs. $37.97 bln Capital IQ Consensus Estimate. Fourth quarter 2014 premiums and fees increased approximately 9% relative to fourth quarter 2013, driven by rate actions, specialty contributions and customer growth in our Commercial business, partially offset by the exit of the Limited Benefits business due to ACA regulation as well as lower government reimbursement rates.

6:06 am Proto Labs beats by $0.01, beats on revs (PRLB) : Reports Q4 (Dec) earnings of $0.43 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.42; revenues rose 27.5% year/year to $56.1 mln vs the $54.37 mln consensus.

Gross margin was 59.9 percent of revenue during the fourth quarter of 2014 compared with 62.7 percent during the same quarter of 2013. The decline reflects an 80 basis point impact of Fineline, which carries a lower gross margin than the legacy products, investments in manufacturing capacity of 80 basis points to support recently launched services and expected growth and a 110 basis point impact of foreign exchange rates.
“During 2015, we will continue to focus on pursuing the growth opportunities we see for the company from our three growth vectors: adding new product developers and engineers, expanding the envelope of our product offerings and commercializing new processes.”

6:06 am Dunkin Brands increases quarterly dividend 15% to $0.265 from $0.23 (DNKN) :  

6:06 am Colfax beats by $0.09, misses on revs (CFX) : Reports Q4 (Dec) adj. earnings of $0.72 per share, $0.09 better than the Capital IQ Consensus Estimate of $0.63; revenues rose 3.0% year/year to $1.21 bln vs the $1.27 bln consensus. Net sales decreased 3.4% organically compared to the fourth quarter of 2013.”We were particularly pleased with the 4.1% increase in orders in the fourth quarter, including some very significant bookings in the oil, gas and petrochemical end market.”

6:02 am Volcano: Philips (PHG) extends tender offer period to acquire Volcano (VOLC) : Philips’ indirect wholly owned subsidiary Clearwater Merger Sub,  is extending the expiration date for its previously announced tender offer until 9:00 a.m., Eastern Time, on February 17, 2015, for all outstanding shares of common stock of Volcano for $18.00 per Volcano share

6:01 am Timmins Gold announces that its 2014 drill program has identified potential satellite deposits on the North Trend located approximately 2-8 km north of the Company’s San Francisco Mine (TGD) : During 2014 Timmins Gold completed a drill program of approximately 25,000 meters in a combination of core, reverse circulation and rotary air blast drilling on the North Trend, a cluster of high priority targets to the north of the San Francisco Mine identified by previous prospecting and exploration.

Highlights of the assays received from the North Trend include 33.85 m of 1.29 g/t Au at 115.5 m downhole, including 11.00 m of 3.69 g/t Au and 1.50 m of 23.90 g/t Au, in hole VT14-002, 13.72 m of 2.54 g/t Au at 59.4 m downhole, including 4.57 m of 4.57 g/t gold and 1.52 m of 19.05 g/t gold, in hole 1B14-036, 9.15 m of 2.66 g/t Au at 24.4 m downhole, including 4.57 m of 5.03 g/t gold, in hole 1B14-013; and 10.2 m of 5.52 g/t Au at 20.3 m downhole including 2.0 m of 25.9 g/t Au, in hole R14-133. Timmins Gold also drilled a total of approximately 3,600 m in a combination of RC and core at the Marisol target approximately 16 km east of the San Francisco Mine. Timmins Gold geological staff concluded that the results did not warrant further work and the option on the property will not be exercised. 

6:01 am W.R. Grace to separate into two public companies (GRA) : The two companies, to be named prior to closing, will be “New Grace,” comprised of Grace’s Catalysts Technologies and Materials Technologies business segments (excluding the Darex packaging business), and “New GCP,” comprised of Grace’s Construction Products business segment and the Darex packaging business.

The separation transaction is intended to be a tax-free spin-off to Grace shareholders for U.S. federal income tax purposes, and is expected to be completed in approximately 12 months.Post separation, the Company expects New Grace to have sales of approximately $1.8 billion (approximately $2.2 billion including sales from our unconsolidated ART JV). The Company believes that New Grace will seek to make strategic bolt-on acquisitions in its core segments as well as acquisitions to expand its high margin, high-performance specialty chemicals and performance materials portfolio. Post separation, the Company expects New GCP to have sales of approximately $1.5 billion

6:01 am RCS Capital announces that its wholesale broker-dealer subsidiaries raised over $275 mln of equity capital in the month of January through 30 direct investment programs vs. $270 mln raised in December 2014 (RCAP) : The Company noted that it saw continuous and steady improvement in equity sales across its diverse platform, including sales of non-traded direct investment programs which were $238 million for January 2015 versus $228 million for December 2014. In addition, average daily sales in the second half of the month increased by 37% versus the first half of the month, in what is traditionally a slow month for equity capital raising. 

6:00 am Lombard Medical receives FDA approval for Aorfix plus endovascular stent graft expanding its addressable market (EVAR) : This new FDA approval now provides the ability for the company to market Aorfix devices between 24mm-36mm in the U.S. Lombard Medical will begin rolling out this expanded range in the second quarter of 2015 with the launch of a 34mm AorfixPlus stent graft in the U.S.

5:56 am On The Wires (:WIRES) :

MoneyGram (MGI) announces that its agent network in Africa has now reached 25,000 locations, following a strategic expansion initiative across the continent. Recent technology advances and new agent and sub-agent signings, including an agreement with the Mauritius Post Office to offer money transfer services at more than 100 locations, have contributed to achieving this company milestone. Toshiba (TOSBF) announced that it has entered into a definitive agreement with SK hynix on joint development of Nano Imprint Lithography. Engineers from the two companies will start development of basic technologies for the process at Toshiba’s Yokohama Complex in Yokohama, Japan in April this year, targeting practical use in 2017. Sonic Foundry (SOFO) announced the University of Bristol selected Mediasite Enterprise Video Platform for lecture capture and video content management. BGC Partners (BGCP) announced that it launched BGC Trader for the Indian Rupee non-deliverable forward market in November 2014.GoPro (GPRO) announced that it will launch a GoPro Channel on the Roku streaming platform this spring. The custom-designed streaming channel will be a one-stop video destination that delivers on-demand GoPro content to millions of Roku customers. 

5:54 am NICE Systems announces resignation of CFO Dafna Gruber; company expects to announce a successor in the next few weeks. (NICE) :  

5:53 am Ormat Tech announces $175 mln agreement with Northleaf Capital Partners for a 40% equity investment in certain power plants at a valuation of $438 million (ORA) : The power plants that will be contributed to the JV as part of the transaction include Ormat’s Puna geothermal power plant in Hawaii, the Don A. Campbell geothermal power plant in Nevada, and nine power plant units across three recovered energy generation assets known as OREG 1, OREG 2, and OREG 3. Ormat will continue to consolidate the JV and its assets, and will continue to provide day-to-day management control, operations and maintenance control over the projects.

The purchase price is subject to upward adjustment based on the closing date of the transaction. Assuming a closing date of February 28, 2015, the purchase price will be $175 million. Additionally, the percentage interest to be acquired by Northleaf is subject to adjustment, based on the Canadian Dollar / US Dollar exchange rate. In the event of such an adjustment, the implied valuation for 100% of the assets would not change, but the proceeds to Ormat would be adjusted based on the percentage interest Northleaf acquires.

5:33 am ABB Ltd misses by $0.05, misses on revs (ABB) : Reports Q4 (Dec) earnings of $0.30 per share, $0.05 worse than the Capital IQ Consensus Estimate of $0.35; revenues fell 9.0% year/year to $10.35 bln vs the $10.74 bln consensus. 

Base orders increased for the sixth consecutive quarter and were up 2% (4% like-for-like), supported by growth initiatives across many businesses, products and geographies. Base orders grew in the two power divisions, reflecting both positive demand from industry customers as well as initiatives in Power Systems to drive growth in base orders that are lower risk and have higher ABB value-added. Base order growth compensated the timing effect of lower large orders, which represented 11% of total orders received in the quarter, compared to 14% in the same quarter in 2013. Service orders represented 18% of total orders. Outlook
The long-term demand outlook in ABB’s three major customer sectors-utilities, industry, and transport and infrastructure-remains clearly positive. Key drivers are the big shift in the electricity value chain, industrial productivity improvements and Industry 4.0, as well as rapid urbanization and the need for energy efficiency in transport and infrastructure.

4:27 am AstraZeneca misses by $0.07, misses on revs; guides FY15 EPS in-line, revs in-line (AZN) : Reports Q4 (Dec) earnings of $0.76 per share, $0.07 worse than the Capital IQ Consensus Estimate of $0.83; revenues fell 2.4% year/year to $6.68 bln vs the $6.8 bln consensus.

Growth platforms up 15% in 2014, contributing 53% of total revenue.Brilinta: +70%, continued global progress.Diabetes: +139%, successful integration of BMS assets, strong Farxiga/Forxiga launch and good uptake of new Bydureon Pen in the US.Respiratory: +10%, with Emerging Markets growth of 27% and decelerating US growth of 15%.Emerging Markets: +12%, with China growth of 22%, making China AstraZeneca’s second largest national market.Japan: -3%, due to mandated price cuts, increased use of generics and Nexium recall in the fourth quarter.Guidance:

Co issues

in-line guidance

for FY15, sees EPS of + low single-digit percent vs. $4.14 Capital IQ Consensus Estimate; sees FY15 revs of +mid single-digit percent vs. $24.97 bln Capital IQ Consensus Estimate.

4:23 am Sanofi-Aventis beats on top and bottom lines (SNY) : Reports FY14 EPS of EUR5.20 vs EUR5.19 Capital IQ consensus; revs increased 5% YoY to EUR33.77 bln vs EUR33.54 bln consensus. 

Growth platforms increased 10.7% to 25,802 millionPharmaceuticals segment grew 4.4%, driven by Diabetes and GenzymeVaccines increased 7.2% and Animal Health grew 6.7%Emerging markets sales delivered 9.3% growth 
2015 financial guidance
Taking into account the outlook for U.S. Diabetes as well as new product launches and late stage pipeline development, 2015 Business EPS is expected to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse eventsApplying December 31, 2014 exchange rates to this full-year 2015 guidance, the additional positive currency impact on 2015 business EPS is estimated to be between 4% and 5%

4:08 am BT Group agrees definitive terms to acquire EE for GBP12.5 bln to create the UK’s leading communications provider (BT) : BT has agreed definitive terms to acquire EE for 12.5bn. The combination of EE and BT will provide customers with innovative, seamless services that combine the power of fibre broadband with wi-fi and advanced mobile capabilities. Integrating the two companies will accelerate BT’s mobility strategy and increase BT’s capacity for future investment and product innovation as it continues to build world-class digital infrastructure in the UK. 

Transaction highlights 

BT announces that it has agreed definitive terms to acquire EE for 12.5bn
EE is the leading mobile network operator in the UK with 31m customers of which 24.5m are direct mobile customers1 and 834,000 are fixed broadband customers. It has the largest 4G customer base of any operator in Europe
The consideration for EE will be payable as a combination of cash and new BT ordinary shares issued to both Deutsche Telekom (DTEGY) and Orange (ORAN)

4:03 am Delphi Automotive beats by $0.05, misses on revs; guides Q1 EPS in-line, revs in-line; guides FY15 EPS in-line, revs in-line (DLPH) : Reports Q4 (Dec) earnings of $1.32 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $1.27; revenues fell 0.7% year/year to $4.15 bln vs the $4.23 bln consensus.

The Company reported fourth quarter 2014 revenue of $4.2 billion, consistent with the prior year period, reflecting continued above-market volume growth in Asia and North America, offset by unfavorable currency impacts. Adjusted for the impacts of currency exchange and commodity movements, revenue increased by 3% in the fourth quarter. This reflects growth of 11% in Asia and 7% in North America, partially offset by declines of 3% in Europe and 9% in South America. Share Repurchase Program

 

During the fourth quarter of 2014, Delphi repurchased 5.04 million shares for approximately $350 million under its existing authorized share repurchase program, leaving approximately $166 million available for future share repurchases

Guidance:
Co issues in-line guidance for Q1, sees EPS of $1.15-1.30 vs. $1.27 Capital IQ Consensus Estimate; sees Q1 revs of $4.15-4.25 vs. $4.2 bln Capital IQ Consensus Estimate. Co issues in-line guidance for FY15, sees EPS of $5.35-5.65 vs. $5.49 Capital IQ Consensus Estimate; sees FY15 revs of $17.1-17.5 vs. $17.23 bln Capital IQ Consensus Estimate.

3:57 am Weatherford reports EPS in-line, misses on revs (WFT) : Reports Q4 (Dec) earnings of $0.32 per share, in-line with the Capital IQ Consensus Estimate of $0.32; revenues fell 0.3% year/year to $3.73 bln vs the $3.9 bln consensus.
Regional Highlights

North America – Fourth quarter revenues of $1.77 billion were down $45 million, or 2% sequentially, and up $197 million, or 13%, over the same quarter in the prior year. Fourth quarter operating income of $283 million (16.0% margin) down 3% sequentially and up 31% from the same quarter in the prior year. The sequential decrease was due to a reduction in activity levels by customers as operators began cutting back on uneconomic activity in December. Latin America – Fourth quarter revenues of $680 million were up $69 million, or 11% sequentially, and up $23 million, or 4%, compared to the same quarter in the prior year. Fourth quarter operating income of $109 million (16.0% margin) was up $19 million, or 21% sequentially, and up $47 million, or 76%, compared to the same quarter in the prior year. The sequential improvements in revenue and operating income were driven by additional well construction activity in Brazil and across all product lines in Colombia.Europe/Sub-Sahara Africa/Russia – Fourth quarter revenues of $526 million were down $118 million, or 18% sequentially, and down $162 million, or 24%, over the same quarter in the prior year.  Fourth quarter operating income of $102 million (19.4% margin) was down $38 million, or 27%, sequentially and was up 117% when compared to the same quarter in the prior year. The sequential decline in revenues and operating income is primarily due to our sale of the pipeline and land drilling and workover rig operations in Russia in the early part of the third quarter.  Sequential revenues were down seasonally in Russia and the North Sea and due to the impact of a markedly weaker Russian ruble. Middle East/North Africa/Asia Pacific – Fourth quarter revenues of $752 million were down $56 million, or 7% sequentially, and down $69 million, or 8%, over the same quarter in the prior year. Fourth quarter operating income of $58 million (7.7% margin) was down 24% sequentially and increased 16% from the same quarter in the prior year.  The decline in revenues and operating income is attributable to lower land rigs revenue partially offset by the contribution from our core product lines, primarily Artificial Lift

3:43 am Vimicro announces $50 mln financing of premium private placement (VIMC) : Co announced that Alpha Spring Limited (the “Investor”), a British Virgin Island company owned by Zongyi Group, has entered into a stock purchase agreement with Vimicro.

Pursuant to the stock purchase agreement entered into on February 5, 2015, Zongyi agrees to make a $50 million investment in Vimicro, with a purchase price of US$2.50 per ordinary share, the equivalent of $10.00 per ADS. Immediately after the closing of the transaction, Zongyi will hold 20 million ordinary shares of Vimicro, approximately 16.3% equity ownership of the Company. The ordinary shares will be subject to a one-year lock-up period. 

2:40 am Actavis to divest rights to branded respiratory portfolio in the U.S. and Canada to AstraZeneca (AZN) (ACT) : Actavis plc (ACT) and AstraZeneca (AZN) announced that they have entered into a definitive agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold. 

AstraZeneca will also pay Actavis an additional $100 million, and Actavis has agreed to a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between AstraZeneca and Actavis. 

2:30 am BioMed Realty reports FFO in-line, revs in-line; guides FY15 FFO in-line; increases Q4 div; issues $0.30 special div (BMR) : Reports Q4 (Dec) funds from operations of $0.36 per share, in-line with the Capital IQ Consensus Estimate of $0.36; revenues rose 4.9% year/year to $165.7 mln vs the $165.91 mln consensus.

Fourth Quarter Distributions

BioMed Realty Trust’s board of directors previously declared a fourth quarter 2014 dividend of $0.26 per share of common stock, which represents a 4.0% increase over the company’s third quarter 2014 dividend of $0.25 per share and is equivalent to an annualized dividend of $1.04 per common share. In addition, the company’s board of directors declared a special dividend of $0.30 per share of common stock reflecting a return to stockholders of a portion of the proceeds from the sale of the 9911 Belward Campus Drive property.

Guidance:

Co issues

in-line guidance

for FY15, sees FFO of $1.39-1.49 vs. $1.44 Capital IQ Consensus Estimate.

2:25 am NXP Semi beats by $0.03, beats on revs; guides Q1 EPS above consensus, revs in-line (NXPI) : Reports Q4 (Dec) earnings of $1.35 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus Estimate of $1.32; revenues rose 18.9% year/year to $1.54 bln vs the $1.51 bln consensus. Co issues mixed guidance for Q1, sees EPS of $1.25-1.35, excluding non-recurring items, vs. $1.22 Capital IQ Consensus Estimate; sees Q1 revs of $1.41-1.47 bln vs. $1.45 bln Capital IQ Consensus Estimate.

2:17 am Intercept Pharma prices 1 mln shares of its common stock at $176.00 per share (ICPT) :  

2:15 am Netflix to launch in Japan this fall (NFLX) : Co announced it will expand this fall into Japan, as it moves to complete its global rollout by the end of 2016. 

2:14 am Matador Resources announces 2014 production results and reserves and 2015 capital budget (MTDR) : Co announced its 2014 year-end production results and reserves and its 2015 capital budget and operating plan. 

2014 Production and Reserves 

2014 total oil production was approximately 3.32 million barrels, a 56% year-over-year increase from approximately 2.13 million barrels of oil produced in 2013. Matador is also pleased to report that its 2014 total natural gas production was approximately 15.3 billion cubic feet, an 18% year-over-year increase from approximately 12.9 billion cubic feet of natural gas produced in 2013. These results are consistent with its operations update on December 8, 2014, except oil production was slightly better than expected, even with adverse weather conditions in the Permian Basin area. Matador’s total oil equivalent production of 5.9 million barrels of oil equivalent, or BOE, represents a 37% increase from approximately 4.3 million BOE produced in 2013. For the year ended December 31, 2014, Matador’s total oil equivalent production averaged approximately 16,100 BOE per day, including average daily oil production of approximately 9,100 barrels of oil per day and average daily natural gas production of 41.9 thousand cubic feet of natural gas per day. In the month of January 2015, Matador’s average daily oil equivalent production was approximately 22,400 BOE per day, including approximately 11,000 barrels of oil per day and 68.5 million cubic feet of natural gas per day, as compared to approximately 6,500 barrels of oil per day and 27.5 million cubic feet of natural gas per day in January 2014. 

2015 Capital Budget and Operating Plan 

2015 capital budget of $350 million, including $267 million for drilling and completions, $38 million for midstream activities in the Permian Basin, $25 million for facilities and infrastructure and $20 million for discretionary land and seismic data  2015 guidance of 8.0 to 8.5 million BOE of total oil equivalent production, an increase of approximately 41% from 20142015 guidance of 4.0 to 4.2 million barrels of oil production, an increase of approximately 23% from 2014 2015 guidance of 24.0 to 26.0 billion cubic feet of natural gas production, an increase of approximately 63% from 2014Adjusted EBITDA guidance of $200 to $220 million, a decrease of approximately 20% from 2014 based on the same estimated average realized prices for 2015 of $50 per barrel for oil and $3.00 per thousand cubic feet for natural gas used to estimate oil and natural gas revenues. 

1:32 am Layne Christensen prices $100 mln of 8.00% Senior Secured Second Lien Convertible Notes (LAYN) :  

1:19 am GNC Holdings announces it stands behind the quality of its products and agrees to temporarily remove a small number of products while working with New York State Attorney General’s Office (GNC) : In making the announcement, the Company said it will provide the Attorney General’s staff with a reasonable opportunity to review GNC’s full and robust response to its questions on, among other things, the standards and procedures GNC follows in authenticating the content of the GNC Herbal Plus products cited in the letter, including finished products testing results based on validated testing protocols. GNC is confident that its response will demonstrate that the five products in question are fully compliant, safe and properly labeled. 

1:10 am Ultragenyx Pharma prices 3 mln shares of its common stock at $54.00 per share (RARE) :  

1:04 am XPO Logistics increases size of previously announced private offering of Senior Notes by $50 mln and prices $400 mln of 7.875% senior notes due 2019 (XPO) :  

12:50 am AmeriGas Partners reports Q1 (Dec) results, misses on revs (APU) : Reports Q1 (Dec) loss of $0.49 per share, may not be comparable to the Capital IQ Consensus Estimate of $1.44; revenues fell 15.0% year/year to $888.8 mln vs the $1.03 bln consensus.

Adj EBITDA was $188.5 million for the first quarter compared with $230.2 million in the prior year. Retail volumes sold for the first quarter decreased 9.1% to 340 million gallons from 374 million gallons in the prior year. The decrease in retail gallons sold reflects temperatures that were 9.6% warmer than the prior year and 6.2% warmer than normal according to the National Oceanic and Atmospheric Administration Guidance:

Following the weather impact we saw in the first quarter, co expects to report Adjusted EBITDA in the range of $635-665 million for the fiscal year ending September 30, 2015. 

12:39 am Allegiant Travel reports Jan traffic increased 5.5% YoY (ALGT) : Co reports preliminary passenger traffic results for January 2015.

Passengers 646,349 +8.2% Revenue passenger miles (000) 626,327 +5.5% Available seat miles (000) 736,961 +4.1% Load factor 85.0% +1.2 pts Departures 4,688 +7.0% 

Guidance – 1st Quarter 2015    

Departures: +8 to 10% ASMs:+4 to 6%  
Investment & Company InformationFinance

Read more:
InPlay from Briefing.com

Comments are closed.